Giunta Alessandro, Ventura Alessandra, Chimenti Maria Sole, Bianchi Luca, Esposito Maria
Department of Dermatology.
Department of Rheumatology, University of Rome Tor Vergata, Rome, Italy.
Drug Des Devel Ther. 2017 Jun 2;11:1643-1651. doi: 10.2147/DDDT.S92128. eCollection 2017.
Psoriasis is a chronic inflammatory disease affecting up to 3% of the general population, associated with discomfort and impaired quality of life. In recent years, the pathogenic cytokine network of psoriasis has been extensively studied leading to the development of new treatments that provide greater efficacy. Interleukin 17A (IL-17A) has been recognized as a crucial cytokine that mediates immunopathogenesis of psoriasis. Ixekizumab - indicated for the treatment of adults with moderate-to-severe plaque psoriasis - is a subcutaneously administered humanized monoclonal antibody that targets IL-17A. A large percentage of patients affected by psoriasis achieved consistent benefits in terms of disease control and rapid onset of action during clinical trials. Overall, ixekizumab brought clinical improvement and a favorable safety profile in phase III trials. Ixekizumab is characterized by consistent efficacy and rapid onset of response; it is not influenced by previous exposure to biologics and has shown good results in areas that are difficult to treat and in severe clinical variants of psoriasis. Ixekizumab has shown significant improvements in the activity of the disease and in those physical functions that inhibit radiographic progression in patients with concomitant involvement of joints. Our data support ixekizumab as a successful therapeutic option for patients affected by moderate-to-severe plaque-type psoriasis.
银屑病是一种慢性炎症性疾病，影响着高达3%的普通人群，会导致不适并降低生活质量。近年来，银屑病的致病细胞因子网络得到了广泛研究，催生了疗效更佳的新疗法。白细胞介素17A（IL-17A）已被确认为介导银屑病免疫发病机制的关键细胞因子。司库奇尤单抗——用于治疗中度至重度斑块状银屑病成人患者——是一种皮下注射的靶向IL-17A的人源化单克隆抗体。在临床试验期间，很大比例的银屑病患者在疾病控制和起效速度方面都持续获益。总体而言，司库奇尤单抗在III期试验中带来了临床改善且安全性良好。司库奇尤单抗具有疗效持久且起效迅速的特点；它不受既往生物制剂治疗的影响，并且在银屑病难以治疗的部位以及严重临床变型中均显示出良好效果。司库奇尤单抗在疾病活动度以及抑制关节受累患者影像学进展的身体功能方面均有显著改善。我们的数据支持司库奇尤单抗作为中度至重度斑块型银屑病患者的一种成功治疗选择。
